Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Driessens

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinomaGregory Driessens, Paul Hoffmann, Michael Pouwels, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2008
Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltrationGregory Driessens, Laurence Gordower, Lise Nuttin, et al.
Prostaglandins & Other Lipid Mediators|August 31, 2006
15-Deoxy-12,14-prostaglandin J2 inhibits interferon gamma induced MHC class II but not class I expression on ARPE cells through a PPAR gamma independent mechanismFrançois Willermain, Simon Dulku, Nathalie Suarez Gonzalez, et al.
Cancer Immunology, Immunotherapy : CII|November 16, 2010
Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF deliveryGregory Driessens, Lise Nuttin, Alain Gras, et al.
Cancer Immunology Research|December 7, 2019
Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint InhibitorsFlorence Schramme, Stefano Crosignani, Kim Frederix, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 17, 2009
A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based libraryZoltan Takacs, Megan Toups, Astrid Kollewe, et al.
Nature|October 21, 2011
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumoursBenjamin Beck, Gregory Driessens, Steven Goossens, et al.
Nature|June 10, 2014
SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinomaSoufiane Boumahdi, Gregory Driessens, Gaelle Lapouge, et al.
The Journal of Clinical Investigation|December 13, 2022
TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in miceSimone A Minnie, Olivia G Waltner, Kathleen S Ensbey, et al.
Molecular Cancer Therapeutics|December 5, 2020
Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist AntibodiesJulie Preillon, Julia Cuende, Virginie Rabolli, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinomaGregory Driessens, Paul Hoffmann, Michael Pouwels, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2008
Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltrationGregory Driessens, Laurence Gordower, Lise Nuttin, et al.
Prostaglandins & Other Lipid Mediators|August 31, 2006
15-Deoxy-12,14-prostaglandin J2 inhibits interferon gamma induced MHC class II but not class I expression on ARPE cells through a PPAR gamma independent mechanismFrançois Willermain, Simon Dulku, Nathalie Suarez Gonzalez, et al.
Cancer Immunology, Immunotherapy : CII|November 16, 2010
Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF deliveryGregory Driessens, Lise Nuttin, Alain Gras, et al.
Cancer Immunology Research|December 7, 2019
Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint InhibitorsFlorence Schramme, Stefano Crosignani, Kim Frederix, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 17, 2009
A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based libraryZoltan Takacs, Megan Toups, Astrid Kollewe, et al.
Nature|October 21, 2011
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumoursBenjamin Beck, Gregory Driessens, Steven Goossens, et al.
Nature|June 10, 2014
SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinomaSoufiane Boumahdi, Gregory Driessens, Gaelle Lapouge, et al.
The Journal of Clinical Investigation|December 13, 2022
TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in miceSimone A Minnie, Olivia G Waltner, Kathleen S Ensbey, et al.
Molecular Cancer Therapeutics|December 5, 2020
Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist AntibodiesJulie Preillon, Julia Cuende, Virginie Rabolli, et al.
Pageof 3